Replies to post #12 on Replimune (REPL)

[jondoeuk]

In the pivotal PhIII trial of ipilimumab, Grade 3 (severe), 4 (life-threatening), or 5 (fatal) AEs occurred in 6.7% of patients treated. In other trials, it ranged from 10-26% [1-3]. In the real-world these may be even higher [4] and then there is the cost.

So based on that I think it makes sense to encode anti-CTLA-4 over anti-PD-1 in the virus. Other reasons are that it blocks Treg activation and/or inhibition of T-cell activation [5,6].

Refs:
1 https://academic.oup.com/annonc/article/21/8/1712/153567
2 http://clincancerres.aacrjournals.org/content/15/17/5591.long
3 https://link.springer.com/article/10.1007%2Fs10637-009-9376-8
4 https://ascopubs.org/doi/full/10.1200/JCO.2015.60.8448
5 http://www.jimmunol.org/content/165/3/1352.long
6 http://jem.rupress.org/content/210/9/1695.long